|
|
Biomarkers for Detection and Prediction of Chemotherapy-Related Cognitive Impairment |
| 3P30CA014520-48S5 |
|
NCI |
2022 |
|
|
Integrative metabolomic characterization of ADHD and asthma comorbidity |
| 5K01HL153941-03 |
|
NHLBI |
2022 |
|
|
Explaining racial and ethnic Alzheimer’s disease disparities with joint estimation of life course social inequities and measurement bias in verbal memory assessment |
| 1F31AG076284-01 |
|
NIA |
2022 |
|
|
Integrated multi-omics approach to identify early protein biomarkers in Alzheimers disease and cognitive decline |
| 1K01AG071689-01A1 |
|
NIA |
2022 |
|
|
Sleep apnea treatment and risk for cognitive decline and Alzheimers disease |
| 1R01AG079391-01 |
|
NIA |
2022 |
|
|
Role and Mechanism of Hearing Impairment in Cognitive Decline and Dementia |
| 3K01AG054693-05S1 |
|
NIA |
2022 |
|
|
Sex-specific cognitive expression and risk in preclinical Alzheimers disease |
| 3R01AG066088-04S1 |
|
NIA |
2022 |
|
|
Identification of the genetic and transcriptomic networks of cognitive and neuropathological resilience to Alzheimer’s disease associated viruses |
| 3U01AG061835-05S1 |
|
NIA |
2022 |
|
|
Alzheimers Disease Genetic Risk and Microglial Innate Immune Memory |
| 5F30AG074618-02 |
|
NIA |
2022 |
|
|
Family history of dementia and APOE e4 status predict neurocognitive trajectories among persons with HIV |
| 5F31AG074838-02 |
|
NIA |
2022 |